Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients-Findings From the International Verapamil SR/Trandolapril Study (INVEST)

American Heart Journal

Volumn 151, Issue 5, 2006, Pages 1072-1079

  Cooper DeHoff, Rhonda M ^a   Aranda Jr , Juan M ^a   Gaxiola, Efrain ^b   Cangiano, Jose L ^c   Garcia Barreto, David ^d   Conti, C Richard ^a   Hewkin, Ann ^e   Pepine, Carl J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Instituto Cardiovascular de Guadalajara   (Mexico)

^c Clinicas Las Americas   (Puerto Rico)

^d INSTITUTO DE CARDIOLOGÍA Y CIRUGÍA CARDIOVASCULAR   (Cuba)

^e ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; HYDROCHLOROTHIAZIDE; TRANDOLAPRIL; VERAPAMIL;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; ETHNOLOGY; FEMALE; FOLLOW UP; HEART INFARCTION; HIGH RISK PATIENT; HISPANIC; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STROKE;

EID: 33646474144     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.05.024     Document Type: Article

References (38)

1. The Hispanic population in the United States: March 2002 (2003), US Census Bureau
2. Wallman K.K., and Hodgdon J. Race and ethnic standards for Federal statistics and administrative reporting. Stat Report (1977) 450-454
3. Hyman D.J., Ogbonnaya K., Taylor A.A., et al. Ethnic differences in nocturnal blood pressure decline in treated hypertensives. Am J Hypertens 13 (2000) 884-891
4. Materson B.J., Reda D.J., Cushman W.C., et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 328 (1993) 914-921
5. Jamerson K., and DeQuattro V. The impact of ethnicity on response to antihypertensive therapy. Am J Med 101 (1996) 22S-32S
6. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157 (1997) 2413-2446
7. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
8. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 290 (2003) 2805-2816
9. Pepine C.J., Handberg-Thurmond E., Marks R.G., et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. J Am Coll Cardiol 32 (1998) 1228-1237
10. Hansson L., Hedner T., and Dahlof B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective randomized open blinded end-point. Blood Press 1 (1992) 113-119
11. Burt V.L., Whelton P., Roccella E.J., et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 25 (1995) 305-313
12. Hajjar I., and Kotchen T.A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 290 (2003) 199-206
13. Glover M.J., Greenlund K.J., Ayala C., et al. Racial/ethnic disparities in prevalence, treatment, and control of hypertension-United States, 1999-2002. MMWR Morb Mortal Wkly Rep 54 (2005) 7-9
14. Sundquist J., Winkleby M.A., and Pudaric S. Cardiovascular disease risk factors among older black, Mexican-American, and white women and men: an analysis of NHANES III, 1988-1994. Third National Health and Nutrition Examination Survey. J Am Geriatr Soc 49 (2001) 109-116
15. Harris M.I., Eastman R.C., Cowie C.C., et al. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 22 (1999) 403-408
16. Winkleby M.A., Fortmann S.P., and Rockhill B. Health-related risk factors in a sample of Hispanics and whites matched on sociodemographic characteristics. The Stanford Five-City Project. Am J Epidemiol 137 (1993) 1365-1375
17. Francis C.K. Hypertension, cardiac disease, and compliance in minority patients. Am J Med 91 (1991) 29S-36S
18. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
19. Sorlie P.D., Backlund E., Johnson N.J., et al. Mortality by Hispanic status in the United States. JAMA 270 (1993) 2464-2468
20. Liao Y., Cooper R.S., Cao G., et al. Mortality from coronary heart disease and cardiovascular disease among adult U.S. Hispanics: findings from the National Health Interview Survey (1986 to 1994). J Am Coll Cardiol 30 (1997) 1200-1205
21. Goff Jr. D.C., Ramsey D.J., Labarthe D.R., et al. Acute myocardial infarction and coronary heart disease mortality among Mexican Americans and non-Hispanic whites in Texas, 1980 through 1989. Ethn Dis 3 (1993) 64-69
22. Hunt K.J., Resendez R.G., Williams K., et al. All-cause and cardiovascular mortality among Mexican-American and non-Hispanic white older participants in the San Antonio Heart Study-evidence against the "Hispanic paradox". Am J Epidemiol 158 (2003) 1048-1057
23. Oh S.S., Corft J.B., Greenlund K.J., et al. Disparities in premature deaths from heart disease-50 states and the District of Columbia, 2001. MMWR Morb Mortal Wkly Rep 53 (2004) 121-125
24. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 23 (1994) 145-158 [discussion 159-60]
25. Narayan K.M., Boyle J.P., Thompson T.J., et al. Lifetime risk for diabetes mellitus in the United States. JAMA 290 (2003) 1884-1890
26. Verdecchia P., Reboldi G., Angeli F., et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 43 (2004) 963-969
27. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997
28. Bengtsson C., Blohme G., Lapidus L., et al. Diabetes incidence in users and non-users of antihypertensive drugs in relation to serum insulin, glucose tolerance and degree of adiposity: a 12-year prospective population study of women in Gothenburg, Sweden. J Intern Med 231 (1992) 583-588
29. Holzgreve H., Nakov R., Beck K., et al. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am J Hypertens 16 (2003) 381-386
30. Tatti P., Pahor M., Byington R.P., et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21 (1998) 597-603
31. Pollare T., Lithell H., Morlin C., et al. Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups. J Hypertens 7 (1989) 551-559
32. Fogari R., Zoppi A., Preti P., et al. Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women. Am J Hypertens 14 (2001) 921-926
33. De Mattia G., Ferri C., Laurenti O., et al. Circulating catecholamines and metabolic effects of captopril in NIDDM patients. Diabetes Care 19 (1996) 226-230
34. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000) 145-153
35. Hansson L., Lindholm L.H., Niskanen L., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353 (1999) 611-616
36. Alderman M.H., Madhavan S., and Cohen H. Antihypertensive drug therapy. The effect of JNC criteria on prescribing patterns and patient status through the first year. Am J Hypertens 9 (1996) 413-418
37. Herrera C.R., Lewin A., Fiddes R., et al. Long-acting diltiazem CD is safe and effective in a hypertensive Mexican-American population. Pharmacotherapy 17 (1997) 1254-1259
38. Lorenzo C., Serrano-Rios M., Martinez-Larrad M.T., et al. Prevalence of hypertension in Hispanic and non-Hispanic white populations. Hypertension 39 (2002) 203-208